Drug-eluting stents have made brachytherapy obsolete

Steven R. Bailey

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of review: This manuscript reviews the controversy regarding the role of intravascular brachytherapy in the setting of growing use of drug eluting stents. The utility of intravascular brachytherapy is being rethought in relation to its use after the placement of drug eluting stents. Even with in-stent stenosis, the role of intravascular brachytherapy is decreasing primarily due to the simplicity of placement of drug eluting stents and the complexity of performing intravascular brachytherapy. Recent findings: The impact of drug eluting stents is already decreasing the clinical impact of in-stent stenosis. The published pivotal clinical restenosis rates from both the Pacitaxil (TAXUS IV) and Sirolimus (SIRIUS) drug eluting stents suggests that the need to perform intravascular brachytherapy will be in fewer than one in 20 patients. Recently reported registry data from Europe and the United states demonstrates the equivalence drug eluting stent implantation to intravascular brachytherapy for in-stent stenosis of bare metal stents. The role of intravascular brachytherapy for in-stent stenosis of drug eluting stents is very much in question. Summary: This manuscript reviews the impact of Drug Eluting Stents in the practice of interventional cardiology and suggests that the need for intravascular brachytherapy will significantly decrease. Whether we will need this therapy at all is very controversial.

Original languageEnglish (US)
Pages (from-to)598-600
Number of pages3
JournalCurrent Opinion in Cardiology
Issue number6
StatePublished - Nov 1 2004


  • Drug eluting stents
  • In-stent stenosis
  • Intravascular brachytherapy
  • Restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Drug-eluting stents have made brachytherapy obsolete'. Together they form a unique fingerprint.

Cite this